@article{article,
  keywords = {autophagy, host-directed therapies, host{\textendash}microbe interactions, mycobacteria, non-tuberculous mycobacteria, vaccines},
  author = {Strong E and Lee S},
  title = {Targeting Autophagy as a Strategy for Developing New Vaccines and Host-Directed Therapeutics Against Mycobacteria.},
  abstract = {<p>Mycobacterial disease is an immense burden worldwide. This disease group includes tuberculosis, leprosy (Hansen{\textquoteright}s disease), Buruli Ulcer, and non-tuberculous mycobacterial (NTM) disease. The burden of NTM disease, both pulmonary and ulcerative, is drastically escalating globally, especially in developed countries such as America and Australia. Mycobacteria{\textquoteright}s ability to inhibit or evade the host immune system has contributed significantly to its continued prevalence. Pre-clinical studies have highlighted promising candidates that enhance endogenous pathways and/or limit destructive host responses. Autophagy is a cell-autonomous host defense mechanism by which intracytoplasmic cargos can be delivered and then destroyed in lysosomes. Previous studies have reported that autophagy-activating agents, small molecules, and autophagy-activating vaccines may be beneficial in restricting intracellular mycobacterial infection, even with multidrug-resistant strains. This review will examine how mycobacteria evade autophagy and discusses how autophagy could be exploited to design novel TB treatment strategies, such as host-directed therapeutics and vaccines, against  and NTMs.</p>},
  year = {2020},
  journal = {Frontiers in microbiology},
  volume = {11},
  pages = {614313},
  month = {01/2020},
  issn = {1664-302X},
  url = {https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7840607/pdf/fmicb-11-614313.pdf},
  doi = {10.3389/fmicb.2020.614313},
  language = {eng},
}